PROGENICS PHARMACEUTICALS IN - COM (PGNX)

CUSIP: 743187106

Q3 2018 13F Holders as of 30 Sep 2018

Type / Class
Equity / COM
Total 13F shares
77,827,881
Share change
+13,054,797
Total reported value
$487,845,823
Put/Call ratio
125%
Price per share
$6.27
Number of holders
137
Value change
+$78,395,961
Number of buys
79
Number of sells
55

Quarterly Holders Quick Answers

What is CUSIP 743187106?
CUSIP 743187106 identifies PGNX - PROGENICS PHARMACEUTICALS IN - COM in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Institutional Holders of PROGENICS PHARMACEUTICALS IN - COM (PGNX) as of Q3 2018

As of 30 Sep 2018, PROGENICS PHARMACEUTICALS IN - COM (PGNX) was held by 137 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 77,827,881 shares. The largest 10 holders included BlackRock Inc., STATE STREET CORP, FEDERATED INVESTORS INC /PA/, ARMISTICE CAPITAL, LLC, Vanguard Group Inc, EAGLE ASSET MANAGEMENT INC, CARILLON TOWER ADVISERS, INC., FARALLON CAPITAL MANAGEMENT LLC, RA CAPITAL MANAGEMENT, LLC, and ARDSLEY ADVISORY PARTNERS. This page lists 137 institutional shareholders reporting positions in this security for the Q3 2018 filing period.
Investor Option Weight % Change % Value $ * Price Shares Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.